|
Name |
Maesopsin
|
Molecular Formula | C15H12O6 | |
IUPAC Name* |
2,4,6-trihydroxy-2-[(4-hydroxyphenyl)methyl]-1-benzofuran-3-one
|
|
SMILES |
C1=CC(=CC=C1CC2(C(=O)C3=C(C=C(C=C3O2)O)O)O)O
|
|
InChI |
InChI=1S/C15H12O6/c16-9-3-1-8(2-4-9)7-15(20)14(19)13-11(18)5-10(17)6-12(13)21-15/h1-6,16-18,20H,7H2
|
|
InChIKey |
LOFYFDPXORJJEE-UHFFFAOYSA-N
|
|
Synonyms |
Maesopsin; 5989-16-2; Mesopsin; 3(2H)-Benzofuranone, 2,4,6-trihydroxy-2-((4-hydroxyphenyl)methyl)-; CHEMBL462109; SCHEMBL9957960; DTXSID90975298; CHEBI:181507; 2,4,6-trihydroxy-2-[(4-hydroxyphenyl)methyl]-1-benzofuran-3-one; LMPK12130072; Maesopsin, >=90% (LC/MS-ELSD); 2,4,6-trihydroxy-2-[(4-hydroxyphenyl)methyl]-1-benzouran-3-one; 2,4,6-Trihydroxy-2-[(4-hydroxyphenyl)methyl]-1-benzofuran-3(2H)-one; NCGC00385382-01!2,4,6-trihydroxy-2-[(4-hydroxyphenyl)methyl]-1-benzofuran-3-one
|
|
CAS | 5989-16-2 | |
PubChem CID | 160803 | |
ChEMBL ID | CHEMBL462109 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 288.25 | ALogp: | 2.2 |
HBD: | 4 | HBA: | 6 |
Rotatable Bonds: | 2 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 107.0 | Aromatic Rings: | 3 |
Heavy Atoms: | 21 | QED Weighted: | 0.671 |
Caco-2 Permeability: | -5.127 | MDCK Permeability: | 0.00000974 |
Pgp-inhibitor: | 0.012 | Pgp-substrate: | 0.02 |
Human Intestinal Absorption (HIA): | 0.031 | 20% Bioavailability (F20%): | 0.95 |
30% Bioavailability (F30%): | 0.97 |
Blood-Brain-Barrier Penetration (BBB): | 0.039 | Plasma Protein Binding (PPB): | 93.40% |
Volume Distribution (VD): | 0.641 | Fu: | 4.81% |
CYP1A2-inhibitor: | 0.82 | CYP1A2-substrate: | 0.44 |
CYP2C19-inhibitor: | 0.179 | CYP2C19-substrate: | 0.061 |
CYP2C9-inhibitor: | 0.477 | CYP2C9-substrate: | 0.902 |
CYP2D6-inhibitor: | 0.584 | CYP2D6-substrate: | 0.67 |
CYP3A4-inhibitor: | 0.877 | CYP3A4-substrate: | 0.214 |
Clearance (CL): | 14.13 | Half-life (T1/2): | 0.867 |
hERG Blockers: | 0.039 | Human Hepatotoxicity (H-HT): | 0.05 |
Drug-inuced Liver Injury (DILI): | 0.928 | AMES Toxicity: | 0.099 |
Rat Oral Acute Toxicity: | 0.073 | Maximum Recommended Daily Dose: | 0.027 |
Skin Sensitization: | 0.89 | Carcinogencity: | 0.117 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.408 |
Respiratory Toxicity: | 0.13 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC002587 | 0.587 | D04XEG | 0.400 | ||||
ENC001438 | 0.541 | D07MGA | 0.384 | ||||
ENC000107 | 0.507 | D04AIT | 0.365 | ||||
ENC001548 | 0.468 | D06TJJ | 0.354 | ||||
ENC001533 | 0.462 | D06KYN | 0.352 | ||||
ENC001550 | 0.462 | D0J7RK | 0.348 | ||||
ENC004231 | 0.447 | D0K8KX | 0.341 | ||||
ENC005357 | 0.430 | D0U3YB | 0.341 | ||||
ENC002571 | 0.429 | D0AZ8C | 0.322 | ||||
ENC002499 | 0.423 | D0S2BV | 0.316 |